Provexis plc (AIM:PXS)

Market Cap	14.66M
Revenue (ttm)	1.29M
Net Income (ttm)	-452.72K
Shares Out	2.35B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,445
Average Volume	1,302,016
Open	0.5894
Previous Close	0.6250
Day's Range	0.5894 - 0.5894
52-Week Range	0.4000 - 0.9500
Beta	0.25
RSI	53.65
Earnings Date	Dec 31, 2025

About Provexis

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product. The company sells its products through company’s website a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 3
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: PXS

Financial Performance

In 2024, Provexis's revenue was 1.29 million, an increase of 61.13% compared to the previous year's 801,964. Losses were -452,720, -22.78% less than in 2023.